Scilight Press

Author Information

Received: 11 Jun 2026 | Revised: 27 Aug 2026 | Accepted: 02 Sep 2026 | Published: 10 Sep 2026

Abstract

Keywords

chimeric antigen receptor | CAR | CAR-T | in vivo CAR-T | quality by design

References 

• 1.

  Bot, A.; Scharenberg, A.; Friedman, K.; et al. In vivo chimeric antigen receptor (CAR)-T cell therapy. Nat. Rev. Drug Discov. 2025, 25, 116–137.

• 2.

  Ascic, E.; Åkerström, F.; Sreekumar Nair, M.; et al. In vivo dendritic cell reprogramming for cancer immunotherapy. Science 2024, 386, eadn9083.

• 3.

  Smith, T.T.; Stephan, S.B.; Moffett, H.F.; et al. In Situ programming of leukaemia‑specific T cells using synthetic DNA nanocarriers. Nat. Nanotechnol. 2017, 12, 813–820.

• 4.

  Heinrich, C.; Spagnoli, F.M.; Berninger, B. In vivo reprogramming for tissue repair. Nat. Cell Biol. 2015, 17, 204–211.

• 5.

  Short, L.; Holt, R.A.; Cullis, P.R.; et al. Direct in vivo CAR T cell engineering. Trends Pharmacol. Sci. 2024, 45, 406–418.

• 6.

  Li, Y.-R.; Zhu, Y.; Halladay, T.; et al. In vivo CAR engineering for immunotherapy. Nat. Rev. Immunol. 2025, 25, 725–744.

• 7.

  Xu, J.; Liu, L.; Parone, P.; et al. In‑vivo B‑cell maturation antigen CAR T‑cell therapy for relapsed or refractory multiple myeloma. Lancet 2025, 406, 228–231.

• 8.

  Wang, Q.; Xiao, Z.X.; Zheng, X.; et al. In vivo CD19 CAR T‑cell therapy for refractory systemic lupus erythematosus. New Engl. J. Med. 2025, 393, 1542–1544.

• 9.

  Harrison, S.; Ho, P.J.; Lim, S.-L.; et al. Minimal residual disease (MRD)‑negative outcomes following a novel, in vivo gene therapy generating anti–B‑cell maturation antigen (BCMA) chimeric antigen receptor (CAR)‑T cells in patients with relapsed and refractory multiple myeloma (RRMM): Preliminary results from inMMyCAR, the first‑in‑human phase 1 study of KLN‑1010. Blood 2025, 146, LBA-1.

• 10.

  Hunter, T.L.; Bao, Y.; Zhang, Y.; et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science 2025, 388, 1311–1317.

• 11.

  Amatya, S.; Green, J.; Chu, C.-S.; et al. Enabling Potent T Cell Delivery and Mitigating Key Off‑Target Concerns of in vivo CAR T Lentiviral Vectors with the Targeted Paramyxovirus Fusogen System. Blood 2024, 144, 2047.

• 12.

  Frank, A.M.; Braun, A.H.; Scheib, L.; et al. Combining T‑cell‑specific activation and in vivo gene delivery through CD3‑targeted lentiviral vectors. Blood Adv. 2020, 4, 5702–5715.

• 13.

  Krug, A.; Saidane, A.; Martinello, C.; et al. In vivo CAR T cell therapy against angioimmunoblastic T cell lymphoma. J. Exp. Clin. Cancer Res. 2024, 43, 262.

• 14.

  Kapitza, L.; Ho, N.; Kerzel, T.; et al. CD62L as target receptor for specific gene delivery into less differentiated human T lymphocytes. Front. Immunol. 2023, 14, 1183698.

• 15.

  Buchholz, C.J.; Mühlebach, M.D.; Cichutek, K. Lentiviral vectors with measles virus glycoproteins–dream team for gene transfer? Trends Biotechnol. 2009, 27, 259–265.

• 16.

  Strebinger, D.; Frangieh, C.J.; Friedrich, M.J.; et al. Cell type‑specific delivery by modular envelope design. Nat. Commun. 2023, 14, 5141.

• 17.

  Nicolai, C.J.; Parker, M.H.; Qin, J.; et al. In vivo CAR T‑cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand. Blood 2024, 144, 977–987.

• 18.

  Michels, K.R.; Sheih, A.; Hernandez, S.A.; et al. Preclinical proof of concept for VivoVec, a lentiviral‑based platform for in vivo CAR T‑cell engineering. J. ImmunoTherapy Cancer 2023, 11, e006292.

• 19.

  Ho, N.; Agarwal, S.; Milani, M.; et al. In vivo generation of CAR T cells in the presence of human myeloid cells. Mol. Ther. Methods Clin. Dev. 2022, 26, 144–156.

• 20.

  Chavan, H.; Amatya, S.; Berlfein, V.; et al. In Vitro and in vivo Specificity and Biodistribution of a Novel CD8‑Targeted Fusosome. Blood 2023, 142, 3630.

• 21.

  Haghighi, E.; Abolmaali, S.S.; Dehshahri, A.; et al. Navigating the intricate in‑vivo journey of lipid nanoparticles tailored for the targeted delivery of RNA therapeutics: A quality‑by‑design approach. J. Nanobiotechnology 2024, 22, 710.

• 22.

  Marshall, A. In Vivo CAR‑Ts Captivate Big Pharma; Nature Publishing Group: New York, NY, USA, 2025.

• 23.

  Lemgart, V.; Richards, J.; Strauss, L.; et al. In Vitro and In vivo Activity of a Lipid Nanoparticle System for the in vivo Generation of CAR T Cells. Blood 2024, 144, 3421.

• 24.

  Cheng, M.H.Y.; Leung, J.; Zhang, Y.; et al. Induction of bleb structures in lipid nanoparticle formulations of mRNA leads to improved transfection potency. Adv. Mater. 2023, 35, 2303370.

• 25.

  Kariko, K.; Buckstein, M.; Ni, H.; et al. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005, 23, 165–175.

• 26.

  Daniel, S.; Kis, Z.; Kontoravdi, C.; et al. Quality by Design for enabling RNA platform production processes. Trends Biotechnol. 2022, 40, 1213–1228.

• 27.

  Adams, G.; Soldevila, F.; Matsuda, D.; et al. In vivo engineering of CAR T cells using a novel targeted LNP‑mRNA technology. J. Immunother. Cancer 2023, 11 (Suppl. S1), A1–A731.

• 28.

  Ma, Y.; VanKeulen‑Miller, R.; Fenton, O.S. mRNA lipid nanoparticle formulation, characterization and evaluation. Nat. Protoc. 2025, 20, 2618–2651

• 29.

  Hunter, T.; Soldevila, F.; Zhang, Y.; et al. A novel product candidate (CPTX2309) for in vivo mRNA engineering of anti‑CD19 CAR T cells utilizing novel CD8‑targeted lipid nanoparticles. Arthritis Rheumatol. 2024, 76, 0019.

• 30.

  Aghajanian, H.; Frantz, A.M.; Riener, R.; et al. Design and Preclinical Development of a Novel In Vivo Chimeric Antigen Receptor (CAR) Product for B-Cell Involved. Cytotherapy 2025, 27, S161.

• 31.

  Mullard, A. In vivo CAR T cells move into clinical trials. Nat. Rev. Drug Discov. 2024, 23, 727–730.

• 32.

  Michels, A.; Ho, N.; Buchholz, C.J. Precision medicine: In vivo CAR therapy as a showcase for receptor‑targeted vector platforms. Mol. Ther. 2022, 30, 2401–2415.

• 33.

  Annoni, A.; Gregori, S.; Naldini, L.; et al. Modulation of immune responses in lentiviral vector‑mediated gene transfer. Cell. Immunol. 2019, 342, 103802.

• 34.

  Wang, Y.; Shao, W. Innate immune response to viral vectors in gene therapy. Viruses 2023, 15, 1801.

• 35.

  Hosseini‑Kharat, M.; Bremmell, K.E.; Prestidge, C.A. Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver‑specific tropism. Mol. Ther. Methods Clin. Dev. 2025, 33, 101436.

• 36.

  Tsoi, K.M.; MacParland, S.A.; Ma, X.-Z.; et al. Mechanism of hard‑nanomaterial clearance by the liver. Nat. Mater. 2016, 15, 1212–1221.

• 37.

  Chan, C.-P.; Jin, D.-Y. Cytoplasmic RNA sensors and their interplay with RNA‑binding partners in innate antiviral response: Theme and variations. Rna 2022, 28, 449–477.

• 38.

  Kouwaki, T.; Nishimura, T.; Wang, G.; et al. RIG‑I‑like receptor‑mediated recognition of viral genomic RNA of severe acute respiratory syndrome coronavirus‑2 and viral escape from the host innate immune responses. Front. Immunol. 2021, 12, 700926.

• 39.

  Brown, B.D.; Sitia, G.; Annoni, A.; et al. In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. Blood 2007, 109, 2797–2805.

• 40.

  Adabi, E.; Charitidis, F.T.; Thalheimer, F.B.; et al. Enhanced conversion of T cells into CAR T cells by modulation of the MAPK/ERK pathway. Cell Rep. Med. 2025, 6, 101970.

• 41.

  Chaturvedi, V.; Green, J.; Zipp, G.; et al. Preclinical Efficacy of a Novel CD8‑Targeted Fusosome for In vivo CAR T Cell Therapy. Blood 2023, 142, 7121.

• 42.

  Charitidis, F.T.; Adabi, E.; Ho, N.; et al. CAR Gene Delivery by T-cell Targeted Lentiviral Vectors is Enhanced by Rapamycin Induced Reduction of Antiviral Mechanisms. Adv. Sci. 2023, 10, 2302992.

• 43.

  Nelson, J.; Sorensen, E.W.; Mintri, S.: et al. Impact of mRNA chemistry and manufacturing process on innate immune activation. Sci. Adv. 2020, 6, eaaz6893.

• 44.

  Moghimi, S.M.; Simberg, D. Pro‑inflammatory concerns with lipid nanoparticles. Mol. Ther. 2022, 30, 2109–2110.

• 45.

  Iroanya, G.I.; Subramanyam, P.N.; Wells, K.D.; et al. Pre‑Existing Anti‑Adeno‑Associated Virus Immunity in Gene Therapy: Mechanisms, Challenges, and Potential Solutions. Hum. Gene Ther. 2025, 36, 1463–1480.

• 46.

  Muhuri, M.; Maeda, Y.; Ma, H.; et al. Overcoming innate immune barriers that impede AAV gene therapy vectors. J. Clin. Investig. 2021, 131, e143780.

• 47.

  Gorovits, B.; Fiscella, M.; Havert, M.; et al. Recommendations for the development of cell‑based anti‑viral vector neutralizing antibody assays. AAPS J. 2020, 22, 24.

• 48.

  Rogers, G.L.; Shirley, J.L.; Zolotukhin, I.; et al. Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid‑specific CD8⁺ T cells. Blood J. Am. Soc. Hematol. 2017, 129, 3184–3195.

• 49.

  Mingozzi, F.; Maus, M.V.; Hui, D.J.; et al. CD8⁺ T‑cell responses to adeno‑associated virus capsid in humans. Nat. Med. 2007, 13, 419–422.

• 50.

  Chen, J.; Wu, Q.; Yang, P.; et al. Determination of specific CD4 and CD8 T cell epitopes after AAV2‑and AAV8‑hF. IX gene therapy. Mol. Ther. 2006, 13, 260–269.

• 51.

  Nathwani, A.C.; Tuddenham, E.G.; Rangarajan, S.; et al. Adenovirus‑associated virus vector–mediated gene transfer in hemophilia B. New Engl. J. Med. 2011, 365, 2357–2365.

• 52.

  Fraietta, J.A.; Lacey, S.F.; Orlando, E.J.; et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 2018, 24, 563–571.

• 53.

  Magni, M.; Jonnalagadda, S.; Bonifazi, F.; et al. CAR T expansion and systemic inflammation: Diverging impacts on large B‑cell lymphoma therapy in the multicenter CART SIE study. Haematologica 2025, 110, 2661.

• 54.

  Zhang, D.K.; Adu‑Berchie, K.; Iyer, S.; et al. Enhancing CAR‑T cell functionality in a patient‑specific manner. Nat. Commun. 2023, 14, 506.

• 55.

  Pfeiffer, A.; Thalheimer, F.B.; Hartmann, S.; et al. In vivo generation of human CD 19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome. EMBO Mol. Med. 2018, 10, e9158.

• 56.

  Agarwal, S.; Weidner, T.; Thalheimer, F.B.; et al. In vivo generated human CAR T cells eradicate tumor cells. Oncoimmunology 2019, 8, e1671761.

• 57.

  Andorko, J.I.; Russell, R.M.; Schnepp, B.C.; et al. Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation. Mol. Ther. 2025, 33, 4937–4952

• 58.

  Beura, E.T.; Latimer, H.J.; Wong, D.; et al. T cell‑specific in vivo transduction with preclinical candidate KLN‑1010 generates BCMA directed CAR T cells with potent anti‑multiple myeloma activity. Cancer Res. 2024, 84 (Suppl. S6), 48.

• 59.

  Contrastano, S.G.; Beura, E.T.; Wong, D.; et al. Potent in vivo Transduction by iGPS Particles Generates CAR T Cells with Durable Anti‑Tumor Activity. In Molecular Therapy; Cell Press 50 Hampshire St, Floor 5: Cambridge, MA, USA, 2023; Volume 31, pp. 48–49.

• 60.

  Billingsley, M.M.; Gong, N.; Mukalel, A.J.; et al. In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism. Small 2024, 20, 2304378.

• 61.

  Zhang, N.; Seo, J.W.; Robinson, E.; et al. Development of an in situ CAR‑T cell protocol through optical and PSMA‑targeted PET imaging. Proc. Natl. Acad. Sci. USA 2025, 122, e2504950122.

• 62.

  Rurik, J.G.; Tombácz, I.; Yadegari, A.; et al. CAR T cells produced in vivo to treat cardiac injury. Science 2022, 375, 91–96.

• 63.

  Mackensen, A.; Müller, F.; Mougiakakos, D.; et al. Anti‑CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 2022, 28, 2124–2132.

• 64.

  Sawyer, A.J.; Lemgart, V.; Kuhlman, W.; et al. Efficient generation of active CAR‑T cells from healthy donors and lymphoma patients. Cancer Res. 2025, 85 (Suppl. S8), 6119.

• 65.

  Tombácz, I.; Laczkó, D.; Shahnawaz, H.; et al. Highly efficient CD4⁺ T cell targeting and genetic recombination using engineered CD4⁺ cell‑homing mRNA‑LNPs. Mol. Ther. 2021, 29, 3293–3304.

• 66.

  Mougiakakos, D.; Krönke, G.; Völkl, S.; et al. CD19‑targeted CAR T cells in refractory systemic lupus erythematosus. New Engl. J. Med. 2021, 385, 567–569.

• 67.

  Berdeja, J.G.; Madduri, D.; Usmani, S.Z.; et al. Ciltacabtagene autoleucel, a B‑cell maturation antigen‑directed chimeric antigen receptor T‑cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE‑1): A phase 1b/2 open‑label study. Lancet 2021, 398, 314–324.

• 68.

  Wu, L.S.; Su, Y.; Li, C.; et al. Population-based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma. Clin. Transl. Sci. 2022, 15, 3000–3011.

• 69.

  Cameau, E.; Zhang, P.; Ip, S.; et al. Process & analytical insights for GMP manufacturing of mRNA lipid nanoparticles. Cell Gene Ther. Insights 2022, 8, 621–635.

• 70.

  Harrison, S.J.; Nguyen, T.; Rahman, M.; et al. CAR+ T‑cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma. Blood 2023, 142, 6939.

• 71.

  Ghilardi, G.; Fraietta, J.A.; Gerson, J.N.; et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat. Med. 2024, 30, 984–989.

• 72.

  Tix, T.; Alhomoud, M.; Shouval, R.; et al. Second primary malignancies after CAR T‑cell therapy: A systematic review and meta‑analysis of 5517 lymphoma and myeloma patients. Clin. Cancer Res. 2024, 30, 4690–4700.

• 73.

  Tang, L.; Cai, D.; Yan, X.; et al. Second-line chimeric antigen receptor T-cell therapy versus standard of care in relapsed or refractory large B‑cell lymphoma: A systematic review and meta‑analysis. Cancer 2026, 132, e70317.

• 74.

  Ruella, M.; Xu, J.; Barrett, D.M.; et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat. Med. 2018, 24, 1499–1503.

• 75.

  Smith, E.C.; Popa, A.; Chang, A.; et al. Viral entry mechanisms: The increasing diversity of paramyxovirus entry. FEBS J. 2009, 276, 7217–7227.

• 76.

  Canelo‑Vilaseca, M.; Sabbah, M.; Di Blasi, R.; et al. Lymphodepletion chemotherapy in chimeric antigen receptor‑engineered T (CAR‑T) cell therapy in lymphoma. Bone Marrow Transplant. 2025, 60, 559–567.

• 77.

  Grosser, R.; Cherkassky, L.; Chintala, N.; et al. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell 2019, 36, 471–482.

• 78.

  Tenchov, R.; Sasso, J.M.; Zhou, Q.A. PEGylated lipid nanoparticle formulations: Immunological safety and efficiency perspective. Bioconjugate Chem. 2023, 34, 941–960.

• 79.

  Hassanel, D.N.B.; Ju, Y.; Takanashi, A.; et al. Influence of hydrophilic polymers on the accelerated blood clearance of mRNA lipid nanoparticles upon repeated administration. Nanoscale Horiz. 2025, 10, 3396–3404.

• 80.

  Stavnsbjerg, C.; Christensen, E.; Münter, R.; et al. Accelerated blood clearance and hypersensitivity by PEGylated liposomes containing TLR agonists. J. Control. Release 2022, 342, 337–344.

• 81.

  Sterner, R.C.; Sterner, R.M. CAR‑T cell therapy: Current limitations and potential strategies. Blood Cancer J. 2021, 11, 69.

• 82.

  Jin, C.; Ma, J.; Ramachandran, M.; et al. CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers. Nat. Biomed. Eng. 2022, 6, 830–841.

• 83.

  Adachi, K.; Sakoda, Y.; Kaisho, T.; et al. CAR‑T cells co‑expressing IL‑7 and CCL19 promote epitope spreading to enhance antitumor immunity. Cancer Immunol. Immunother. 2026, 75, 68.

• 84.

  Argueta, S.; Wang, Y.; Zhao, H.; et al. In vivo programmed myeloid cells expressing novel chimeric antigen receptors show potent anti-tumor activity in preclinical solid tumor models. Front. Immunol. 2024, 15, 1501365.